Stock AnalizElanco Animal Health (ELAN) earnings for the quarter ended September 2026: EPS beats estimates
Elanco Animal Health reported results for the quarter ended September 2026 on November 6, 2026. Adjusted earnings per share came in at $0.27 against the analysts’ average forecast of $0.20, a beat of 32.8%.
Revenue for the quarter was $1.26 billion, up 11.3% from $1.14 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 8.7% on the first trading day after the report.
The last four quarters
Elanco Animal Health has beaten the analysts’ EPS forecast in 4 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $0.27 | $0.20 | +32.8% | +11% | +8.7% |
| Jun 2026 | $0.34 | $0.27 | +26.5% | +10% | −5.5% |
| Mar 2026 | $0.40 | $0.34 | +16.6% | +15% | +4.4% |
| Dec 2025 | $0.13 | $0.12 | +11.2% | +12% | +8.4% |
What comes next
Analysts expect EPS of $0.17 for the next quarter on average and $1.18 for the fiscal year ending December 31, 2026.
The average analyst price target is $31.00, 16% above the current price of $26.78.
Valuation and score
Elanco Animal Health scores 1.0 out of 5 overall on Stock Analiz (weak), and its intrinsic value under moderate assumptions is about 80% below the current market value. Full Elanco Animal Health analysis with 10 years of financials
Frequently asked questions
What was Elanco Animal Health’s EPS for the quarter ended September 2026?
$0.27 adjusted per share, against an analyst consensus of $0.20.
How much revenue did Elanco Animal Health report?
$1.26 billion, up 11.3% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.